GeoVax Labs Files 8-K Report
Ticker: GOVX · Form: 8-K · Filed: Oct 16, 2024 · CIK: 832489
Sentiment: neutral
Topics: 8-K, other-event
Related Tickers: GOVX
TL;DR
GeoVax Labs filed an 8-K on Oct 16th - something happened.
AI Summary
On October 16, 2024, GeoVax Labs, Inc. filed an 8-K report detailing an "Other Event." The filing does not provide specific details about the event itself, but it indicates a material development for the company. The report was filed from Smyrna, Georgia.
Why It Matters
This 8-K filing signals a significant, though unspecified, event for GeoVax Labs, Inc. that may impact its business operations or stock performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the 8-K filing creates uncertainty, which can be a risk for investors.
Key Players & Entities
- GeoVax Labs, Inc. (company) — Registrant
- October 16, 2024 (date) — Date of report
- Smyrna, Georgia (location) — Company location
FAQ
What specific event is reported in the 8-K filing by GeoVax Labs, Inc. on October 16, 2024?
The filing is an 8-K report for an 'Other Event' and does not specify the nature of the event.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 16, 2024.
Where is GeoVax Labs, Inc. headquartered?
GeoVax Labs, Inc. is located at 1900 Lake Park Drive, Suite 380, Smyrna, GA 30080.
What is the Commission File Number for GeoVax Labs, Inc.'s 8-K filing?
The Commission File Number is 001-39563.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This 8-K report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-10-16 16:29:43
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share GOVX The Nasdaq Capital M
Filing Documents
- govx20241016_8k.htm (8-K) — 25KB
- 0001437749-24-031364.txt ( ) — 170KB
- govx-20241016.xsd (EX-101.SCH) — 4KB
- govx-20241016_def.xml (EX-101.DEF) — 13KB
- govx-20241016_lab.xml (EX-101.LAB) — 17KB
- govx-20241016_pre.xml (EX-101.PRE) — 13KB
- govx20241016_8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events. The Company re-convened a Special Meeting of Stockholders (the "Special Meeting") on October 16, 2024 (originally convened on September 17, 2024) and adjourned the Special Meeting without any business being conducted due to lack of the required quorum. The Company has determined to keep the polls open and reconvene the Special Meeting on November 12, 2024 at 8:30 a.m. Eastern Time to provide its stockholders additional time to vote on the proposals described in the proxy statement filed with the Securities and Exchange Commission on August 1, 2024. No changes have been made to the proposals to be voted on by stockholders at the Special Meeting. At the time the Special Meeting was adjourned, proxies had been submitted by stockholders representing approximately 28.6% of the shares of the Company's common stock outstanding and entitled to vote. Proxies previously submitted in respect of the Special Meeting will be voted at the reconvened Special Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GeoVax Labs, Inc. October 16, 2024 By: /s/ Mark W. Reynolds Name: Mark W. Reynolds Title: Chief Financial Officer